Latest Glycogen storage disease type II Stories
CRANBURY, N.J., Nov.
NOVATO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received orphan drug designation from the U.S.
NOVATO, Calif., Aug. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has acquired ZyStor Therapeutics, Inc.
CRANBURY, N.J., Aug.
The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered today (Wednesday, June 16) at the University of Florida.
SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S.
SILVER SPRING, Md., May 24 /PRNewswire-USNewswire/ -- Genzyme Corp.
CRANBURY, N.J., May 6 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the quarter ended March 31, 2010 and reviewed the progress on its product development pipeline including an update that the Company does not plan to advance AT2220, its investigational drug AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe disease, as a monotherapy at this time.
MONTREAL, March 29 /PRNewswire/ -- Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting.
NEW YORK, Feb.
- A serpent whose bite was fabled to produce intense thirst.